Awards were announced in six categories: Business of the Year (1-50 employees), Business of the Year (51-100 employees), Business of the Year (101+ employees), Corporate Citizen of the Year, Emerging Business of the Year and Executive of the Year.
Prism Capital Partners has sold a 157,000-square-foot life sciences building at its ON3 campus, in a sign of investor appetite for modern lab and research and development space.
Construction is scheduled to begin in the first quarter of 2021 on a build-to-suit medical office building at Prism Capital Partners’ ON3 campus. The firm received final site plan approval this fall for the 80,000 s/f facility, which has been pre-leased by Hackensack Meridian Health.
As we close out 2020, NJBIZ’s final virtual event of the year is the Business of the Year Awards which recognizes companies and their leaders who are striving for excellence, growing and contributing to the New Jersey business community.
Involved in a number of multifamily projects, but securing Eisai (and up to 1,200 employees) as an anchor tenant at the Roche tower in its ON3 project in Nutley-Clifton is the biggest office deal of the year.
Prism Capital Partners, in a joint venture with Northwestern Mutual Life Insurance Co., is nearing completion of 10 Green Street at Woodbridge Station, a 232-unit multifamily project located south of Newark in Woodbridge.
The year 2020 has been a long and hard slog for everyone, including the experts in the multifamily field. To be sure, apartments have weathered the pandemic relatively well, holding onto their private-market value and staying relatively flush with capital thanks in part to the GSEs.
Prism Capital Partners announced on Thursday that it has opened up the last remaining block of new apartments to lease at its luxury rental community in West Orange.
Prism Capital Partners is eyeing a June completion date for its conversion and restoration of a historic Wonder Bread factory in Hoboken, where it will deliver 89 new residential units.
Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo) announced the relocation of its New Jersey-based headquarters to the technologically-advanced and cutting-edge ON3 property in Nutley.